SUNNYVALE, Calif.—Johnson Amal M, a director at Intuitive Surgical Inc . (NASDAQ:ISRG), a $204.6 billion medical technology company trading near its 52-week high, recently sold 4,635 shares of the company's common stock. The shares were sold at an average price of $566.60 per share, resulting in a total transaction value of approximately $2.63 million. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
The transaction was executed as part of a pre-arranged trading plan compliant with SEC Rule 10b5-1, which allows insiders to set up a predetermined schedule for selling stocks. Following the sale, Johnson's direct ownership in the company stands at 12,275 shares. The stock has delivered an impressive 51.4% return over the past year, with InvestingPro data showing strong financial health metrics.
Prior to the sale, Johnson exercised options to acquire 4,635 shares of Intuitive Surgical's common stock at a price of $90.4944 per share, totaling approximately $419,441. The options were granted under the company's Non-Employee Directors' Stock Option Plan. With a P/E ratio of 88.3, the stock trades at premium multiples, reflecting market confidence in its growth prospects. Discover more insights and 14 additional ProTips with a subscription to InvestingPro.
In other recent news, Intuitive Surgical has seen a flurry of activity from various analyst firms. RBC Capital Markets maintained an Outperform rating, setting a price target of $641, citing the company's strong fourth-quarter performance in 2024, where it exceeded expectations with a 10% and 24% beat on revenue and earnings per share (EPS), respectively. Meanwhile, Piper Sandler raised the price target on Intuitive Surgical shares to $670, maintaining an Overweight rating, following the company's impressive fourth-quarter earnings report which surpassed consensus expectations for both revenue and earnings.
Oppenheimer held a Perform rating despite the company's strong results and a significant distribution agreement worth €290 million, expected to close by 2026. Bernstein analysts reaffirmed an Outperform rating for Intuitive Surgical, setting a price target of $700, based on the company's strong financial performance in the last quarter and the company's growth prospects supported by five transformational product cycles.
Truist Securities increased the price target to $666, maintaining a Buy rating. The firm's analysts believe that Intuitive Surgical is well-positioned to maintain a mid-to-high-teens revenue and profit compound annual growth rate (CAGR) over the next two to three years. Deutsche Bank (ETR:DBKGn) analysts increased the price target for Intuitive Surgical shares to $585, while keeping a Hold rating on the stock. These are the recent developments in the company's journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.